Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

Japan Health Authority approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara

The biosimilar Ustekinumab has been developed and manufactured by the company

Alembic receives USFDA final approval for Paliperidone ER tablets

Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia

Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan

Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025

Wanbury appoints Pradeep Patni as CEO of India Formulation Business

Patni brings over 25 years of distinguished experience in the pharmaceutical industry

Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

The approval marks a significant milestone for the American pharmaceutical company in the field of UC

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals